Trial Profile
A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FIDeS
- 30 Jun 2009 New trial record